| Target Validation Information | |||||
|---|---|---|---|---|---|
| TTD ID | T14143 | ||||
| Target Name | Transforming growth factor beta 2 (TGFB2) | ||||
| Type of Target |
Clinical trial |
||||
| Action against Disease Model | AP12009 | Drug Info | Trabedersen (AP 12009) is a phosphorothioate antisense oligodeoxynucleotide specific for h uMan TGF-|?? mRNA. Trabedersen reduced TGF-|?? secretion in h uMan pancreatic cell lines with an IC(50) in the low |?M range without transfection reagent, clearly inhibited cell proliferation, and completely blocked migration of pancreatic cancer cells. Additionally, trabedersen reversed TGF-|??-mediated immunosuppression of pancreatic cancer cells targeted by lymphokine activated killer (LAK) cells, resulting in considerably increased LAK cell-mediated cytotoxicity. Moreover, in an orthotopic mouse model of metastatic pancreatic cancer, intraperitoneal (i.p.) treatment with trabedersen significantly reduced t uMor growth, lymph node metastasis and angiogenesis. | [1] | |
| References | |||||
| REF 1 | Transforming growth factor-beta 2 gene silencing with trabedersen (AP 12009) in pancreatic cancer. Cancer Sci. 2011 Jun;102(6):1193-200. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.